Three logos for walpole tms new england center and cape tms
Forms & Policies

Walpole MA

508-734-5893


Forms & Policies

Acton MA

978-679-1200

Forms & Policies

East Falmouth MA

508-388-7493

SpravatoTreatment
A woman with long hair is standing next to a purple flower.
A nasal spray is sitting in a circle on a yellow and orange background.

SPRAVATO®

for Treatment-Resistant Depression (TRD)

  • Proven efficacy with safety evaluated in over 1700 adults with treatment-resistant depression (TRD) across six studies: Five Phase 3 studies and one Phase 2 dose ranging study1


What is Spravato?

SPRAVATO® is designed for use together with an oral antidepressant for:

- Adults dealing with treatment-resistant depression (MDD patients who have not responded adequately to 2 or more oral antidepressants)

- Adult MDD patients experiencing depressive symptoms with acute suicidal thoughts or behaviors (MDSI)


Usage Limitations:

The efficacy of SPRAVATO® in preventing suicide or decreasing suicidal thoughts or behaviors has not been proven. Even if patients show improvement after an initial dose, the need for hospitalization should not be ruled out if clinically necessary.


SPRAVATO® is not authorized for use as an anesthetic agent, as its safety and effectiveness in this regard have not been determined.

A logo for a 28 mg nasal spray called spravato

A distinct treatment approach

FDA-approved for over 4 years

Nasal spray formulation


Use and Restrictions:

SPRAVATO® (esketamine) CIII Nasal Spray is prescribed alongside an oral antidepressant to address:

- Treatment-resistant depression (TRD) in adults.

- Depressive symptoms in adults with major depressive disorder (MDD) exhibiting acute suicidal ideation or behavior.

Restrictions:

The efficacy of SPRAVATO® in preventing suicide or diminishing suicidal thoughts/behavior has not been proven. The use of SPRAVATO® does not eliminate the need for hospitalization if deemed clinically necessary, even if there is improvement following initial SPRAVATO® administration.

SPRAVATO® is not approved as an anesthetic. The safety and efficacy of SPRAVATO® as an anesthetic have not been established.

SPRAVATO® combined with an oral antidepressant demonstrated rapid and superior enhancement in depressive symptoms versus placebo + oral AD and provides your patients with a consistent safety profile and minimal risk of sexual dysfunction.

A brochure for a product called sprovato is open to a page with a syringe on it.
Read the Brochure

NECHM Information Request Form

NECHM Information Request Form

A logo for a 28 mg nasal spray called spravato
  • A different treatment approach
  • FDA-approved for over 4 years
  • Nasal spray formulation


Indications and Limitations of Use:

SPRAVATO® (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of:

  • Treatment-resistant depression (TRD) in adults.
  • Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Limitations of Use:

  • The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®.
  • SPRAVATO® is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO® as an anesthetic agent have not been established.

SPRAVATO® + oral AD demonstrated rapid and superior improvement in depressive symptoms compared to placebo + oral AD and offers your patients a consistent safety profile with minimal risk for sexual dysfunction


A brochure for a product called sprovato is open to a page with a syringe on it.
Read the Brochure

NECHM Information Request Form

Patients with the following condition have reported positive outcomes with ketamine therapy:


Share by: